coptisine has been researched along with Alloxan Diabetes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M; Li, X; Li, Z; Ma, L; Ma, Z; Zhai, J; Zhang, H; Zhang, Y; Zou, J | 1 |
| Chen, X; Du, GH; Fang, LH; Jia, WH; Qiang, GF; Shi, LL; Wang, NQ; Xu, CY; Yang, XY; Yin, L; Zhang, L | 1 |
2 other study(ies) available for coptisine and Alloxan Diabetes
| Article | Year |
|---|---|
Coptisine ameliorates renal injury in diabetic rats through the activation of Nrf2 signaling pathway.
Topics: Animals; Berberine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Heme Oxygenase (Decyclizing); Kidney; Male; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Protective Agents; Rats, Sprague-Dawley; Signal Transduction | 2020 |
Glucose consumption assay discovers coptisine with beneficial effect on diabetic mice.
Topics: AMP-Activated Protein Kinases; Animals; Berberine; Blood Glucose; Diabetes Mellitus, Experimental; Enzyme Activation; Extracellular Space; Hep G2 Cells; Humans; Hypoglycemic Agents; Liver; Male; Mice; Mitochondria; Muscle, Skeletal; Rats | 2019 |